Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139231 | 0.83 | IRAK4 (0.66) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL12800226 | 0.80 | IRAK4 (1.00) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL10077600 | 0.77 | IRAK4 (0.67) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL24755152 | 0.77 | HDAC6 (1.00) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2138888 | 0.77 | IRAK4 (0.74) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL2141251 | 0.77 | IRAK4 (0.71) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL11388948 | 0.76 | HDAC6 (0.78) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL28970478 | 0.76 | HDAC6 (0.78) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL4734401 | 0.74 | HDAC6 (0.70) | IRAK4NPC1RAB9AMAPK1ATM | |
| SCHEMBL29609228 | 0.74 | IRAK4 (0.66) | IRAK4NPC1RAB9AMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148411-B2 | 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER SCHERING PHARMA AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203715-A1 | NOVEL 2-HETARYLTHIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CNR2, CYP11B2, CYP2C19 | IRAK4 788/4885NPC1 182/4885RAB9A 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.